West Pharmaceutical Services
) inked an agreement with Janssen Biotech, Inc. to develop and
manufacture a leading-edge self-injection product. Per the
agreement, West will market the latest self-injection technology,
aptly named SelfDose.
SelfDose, developed by Janssen Biotech will meet patient needs
by simplifying self-injection technology for various pharmaceutical
and biologic drugs. The collaboration will enable West to enhance
its existing portfolio of self-injection technology as it is under
obligation to co-develop and commercialize SelfDose. Janssen
Biotech's latest offering delivers advanced manual injection and
complements West's ConfiDose and SmartDose injection
The agreement allows West to provide technological and
regulatory support to Janssen Biotech. Management at West is
optimistic about its collaboration with Janssen Biotech as the
opportunity will enable the company to meet its business goals.
West's undertaking for business expansion while providing
quality solutions to its consumers is rooted in this recent
collaboration. According to the company, SelfDose can eliminate the
problems emanating from the lack of a safe and effective medication
delivery mechanism, especially when the administrator is the
West is a global leader in provision of drug administration
systems and components for packaging, as well as delivery of
injectable drugs and delivery system components across various
industries. The company has a significant competitive advantage in
the market it serves. Additionally, it continues to make headway
into new geographies to expand its business.
However, macroeconomic pressure across the globe remains a
West, which competes with
), currently has a Zacks #2 Rank, which translates into a
short-term Buy rating.
REXAM PLC-ADR (REXMY): Free Stock Analysis
WEST PHARM SVC (WST): Free Stock Analysis
To read this article on Zacks.com click here.